New research has identified how bone cells subdue cancer cells that have reached the bone so that the cancer cells remain dormant for decades. The finding may help researchers develop new treatments to prevent or treat metastatic disease and put cancer cells to sleep permanently.
Patients who are treated for their primary cancer may have it return in their bones 20 or even 30 years later. Now, new research published in Breast Cancer Research may have identified why this phenomenon happens, which in turn may help researchers identify new treatments to permanently stop the growth of cancer cells.
The study identified a type of bone cell that subdues cancer cells and slows their growth so that the cancer cells can remain in a sleeping state and reawaken decades later.
“Cancer has this uncanny ability to turn other cell types it comes in contact with to the cancer cell’s advantage,” Karen Bussard, PhD, coauthor, assistant professor of cancer biology at Thomas Jefferson University and a researcher at the Sidney Kimmel Cancer Center, Jefferson Health, said in a statement. “For example, cancer cells can turn the immune cells that should kill it, into its own guards. However, we have now found a population of bone cells that not only resists but subdues the cancer. It’s fascinating.”
The researchers studied the tumor-bearing tibia of mice for the presence of osteoblasts and analyzed tissue from patients with bone metastatic breast cancer for osteoblast subpopulations.
They found that once osteoblast cells in both mice and humans interacted with bone metastatic breast cancer cells, they were drastically changed. Once cancer cells enter the bone, osteoblasts change their function toward producing factors that halt cancer cell growth.
The findings could help develop new strategies to prevent or treat metastatic disease. Next, the researchers will fully characterize the molecules used by osteoblasts to slow cancer growth. It might be possible that understanding the function of these osteoblasts could provide treatments that put cancer cells to sleep permanently.
“The bone-building osteoblast cells have a complex relationship with cancer,” Bussard said. “In advanced stages of the disease, we know that metastatic breast cancer cells can co-opt the normal cells of the bone to help cancer metastases thrive. However, our new work suggests that during early stages of the disease, such as when metastatic breast cancer cells first migrate to the bone, these cancer-exposed osteoblasts resist and fight cancer growth.”
Reference
Kolb AD, Shupp AB, Mukhopadhyay D, Marini FC, Bussard KM. Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 2019;21(1):31. doi: 10.1186/s13058-019-1117-0.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More